Aytu BioPharma (NASDAQ:AYTU) Announces Quarterly Earnings Results

Aytu BioPharma (NASDAQ:AYTUGet Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.28) EPS for the quarter, Zacks reports. Aytu BioPharma had a negative return on equity of 21.89% and a negative net margin of 8.28%.

Aytu BioPharma Trading Down 2.1 %

NASDAQ AYTU traded down $0.03 during trading on Wednesday, hitting $1.39. The stock had a trading volume of 57,227 shares, compared to its average volume of 24,390. The company has a market capitalization of $8.55 million, a PE ratio of -1.13 and a beta of -1.45. The company has a quick ratio of 0.80, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. Aytu BioPharma has a twelve month low of $1.30 and a twelve month high of $3.45. The firm has a 50 day moving average price of $1.62 and a 200 day moving average price of $2.01.

Aytu BioPharma Company Profile

(Get Free Report)

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.

See Also

Earnings History for Aytu BioPharma (NASDAQ:AYTU)

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.